Tectonic Therapeutic (NASDAQ:TECX) Rating Lowered to Strong Sell at Wall Street Zen

Posted by Geri Gentry on Sep 21st, 2026

Tectonic Therapeutic (NASDAQ:TECX – Get Free Report) was downgraded by equities researchers at Wall Street Zen from a “sell” rating to a “strong sell” rating in a research report issued to clients and investors on Saturday, Wall Street Zen reports.

TECX has been the subject of a number of other research reports. Weiss Ratings reiterated a “sell (d-)” rating on shares of Tectonic Therapeutic in a research report on Friday, July 17th. Zacks Research raised Tectonic Therapeutic from a “strong sell” rating to a “hold” rating in a research report on Tuesday, August 18th. Oppenheimer restated an “outperform” rating on shares of Tectonic Therapeutic in a research note on Tuesday, September 1st. Raymond James Financial raised shares of Tectonic Therapeutic from an “outperform” rating to a “strong-buy” rating and upped their price target for the company from $76.00 to $81.00 in a research report on Tuesday, May 26th. Finally, Wells Fargo & Company lowered their price objective on shares of Tectonic Therapeutic from $101.00 to $93.00 and set an “overweight” rating on the stock in a research note on Friday, August 7th. Two research analysts have rated the stock with a Strong Buy rating, four have given a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $77.25.

Get Our Latest Report on TECX

Tectonic Therapeutic Price Performance

Shares of Tectonic Therapeutic stock opened at $27.00 on Friday. Tectonic Therapeutic has a 1 year low of $14.39 and a 1 year high of $39.53. The firm’s 50-day moving average is $31.85 and its 200 day moving average is $30.86. The stock has a market cap of $527.85 million, a price-to-earnings ratio of -5.91 and a beta of 3.31.

Tectonic Therapeutic (NASDAQ:TECX – Get Free Report) last released its quarterly earnings data on Thursday, August 6th. The company reported ($1.18) EPS for the quarter, beating the consensus estimate of ($1.35) by $0.17. On average, equities analysts expect that Tectonic Therapeutic will post -5.27 EPS for the current fiscal year.

Institutional Investors Weigh In On Tectonic Therapeutic

Hedge funds and other institutional investors have recently modified their holdings of the stock. First Light Asset Management LLC increased its position in Tectonic Therapeutic by 23.6% in the second quarter. First Light Asset Management LLC now owns 800,726 shares of the company’s stock worth $27,525,000 after buying an additional 152,983 shares in the last quarter. Velan Capital Investment Management LP purchased a new position in shares of Tectonic Therapeutic during the 2nd quarter valued at about $206,000. Wellington Management Group LLP grew its stake in shares of Tectonic Therapeutic by 7.5% during the 2nd quarter. Wellington Management Group LLP now owns 31,432 shares of the company’s stock valued at $1,080,000 after acquiring an additional 2,192 shares during the period. Bank of America Corp DE bought a new position in shares of Tectonic Therapeutic during the 2nd quarter valued at approximately $380,000. Finally, 5AM Venture Management LLC bought a new position in shares of Tectonic Therapeutic during the 2nd quarter valued at approximately $20,853,938. 62.63% of the stock is currently owned by hedge funds and other institutional investors.

Tectonic Therapeutic Company Profile

(Get Free Report)

Tectonic Therapeutic, Inc is a clinical-stage biotechnology company focused on developing biologic medicines that target G protein-coupled receptors (GPCRs). These receptors play important roles in many physiological processes but have historically been difficult to address with conventional antibody-based therapies.

The company uses its proprietary GEODe platform to discover and develop antibodies and other biologics designed to modulate GPCR activity. Tectonic’s pipeline includes TX45, an investigational therapeutic intended to activate the relaxin receptor RXFP1.